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AbstrACt
Objectives To compare the rate, indications and type 
of antibiotic prescriptions in children with and without 
asthma.
Design A retrospective cohort study.
setting Two population-based primary care databases: 
Integrated Primary Care Information database (IPCI; the 
Netherlands) and The Health Improvement Network (THIN; 
the UK).
Participants Children aged 5–18 years were included 
from January 2000 to December 2014. A child was 
categorised as having asthma if there were ≥2 
prescriptions of respiratory drugs in the year following a 
code for asthma. Children were labelled as non-asthmatic 
if no asthma code was recorded in the patient file.
Main outcome measures Rate of antibiotic prescriptions, 
related indications and type of antibiotic drugs.
results The cohorts in IPCI and THIN consisted of 946 143 
and 7 241 271 person years (PY), respectively. In both 
cohorts, antibiotic use was significantly higher in asthmatic 
children (IPCI: 197vs126 users/1000 PY, THIN: 374vs250 
users/1000 PY). In children with asthma, part of antibiotic 
prescriptions were for an asthma exacerbation only (IPCI: 
14%, THIN: 4%) and prescriptions were more often due to 
lower respiratory tract infections then in non-asthmatic 
children (IPCI: 18%vs13%, THIN: 21%vs12%). Drug type 
and quality indicators depended more on age, gender and 
database than on asthma status.
Conclusions Use of antibiotics was higher in asthmatic 
children compared with non-asthmatic children. This was 
mostly due to diseases for which antibiotics are normally 
not indicated according to guidelines. Further awareness 
among physicians and patients is needed to minimise 
antibiotic overuse and limit antibiotic resistance.
IntrODuCtIOn 
Antibiotic resistance is one of the biggest 
threats to global health today, as recently 
stated by the WHO.1 Antibiotic resistance 
leads to higher medical costs, prolonged 
hospital stays and increased mortality.2 The 
world urgently needs to change the way it 
prescribes and uses antibiotics. The Neth-
erlands has long been recognised as a role 
model in the restricted use of antibiotics. 
For example, due to restricted antibiotic use, 
methicillin-resistant Staphylococcus aureus rates 
are much lower in the Netherlands than in 
surrounding countries.3 4 Insights in antibi-
otic use for different patient groups and in 
different countries may help to develop best 
practices for optimal antibiotic use.
Studies indicate that children with asthma 
receive more antibiotics than children 
without asthma.5 6 However, national and 
international guidelines clearly state that 
antibiotics are not indicated for an asthma 
exacerbation.7–9 Respiratory infections may 
trigger an asthma exacerbation, but these are 
mostly viral infections.7 Insight in prescription 
patterns is a first step in detecting possible 
overuse and to initiate steps in reducing 
antibiotic use. Not only the prescription 
rate influences resistance patterns, also the 
type of antibiotic is important. Indeed, it is 
well known that broad spectrum antibiotics 
increase the risk of resistance more than 
narrow spectrum antibiotics.10
The aim of this study was to investigate 
differences in antibiotic prescriptions rates, 
type of antibiotic being prescribed and 
related indications in children with and 
without asthma in a primary care setting in 
different countries. In addition, we studied 
changes over time and associated quality 
indicators (QIs).
strengths and limitations of this study
 ► This study investigates antibiotic prescriptions in 
two large population-based databases.
 ► A major strength of this study is that the use of 
databases from different countries surpasses local 
prescription patterns.
 ► Because of the design of the study, misclassification 
of indications is possible.
 ► Antibiotic use depends on country, sex and gender; 
therefore, analyses were stratified.
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PAtIents AnD MethODs
setting
A retrospective, population-based cohort study was 
conducted using data from two primary care databases: 
the Integrated Primary Care Information database (IPCI) 
from the Netherlands and The Health Improvement 
Network (THIN) from the UK. Both databases contain 
detailed information on drug prescription, diagnoses and 
co morbidities. Detailed descriptions of these databases 
have been published elsewhere.11–13
Patient and public involvement
No patients and or public were involved in this study.
study population
The study population comprised all children aged 5–18 
years, with at least 1 year of valid database history and 
having at least 1 day of follow-up during the study period 
(from 1 January 2000 to 31st December 2014). Within this 
study population, we identified a cohort of children with 
asthma and a cohort of children without asthma. A child 
was diagnosed as having asthma if there were at least two 
prescriptions of respiratory drugs in the year following a 
code for asthma. These drugs consisted of bronchodila-
tors, inhaled corticosteroids, leukotriene receptor antag-
onist or xanthines (Anatomical Therapeutic Chemical 
Classification System (ATC) code R03; British National 
Formulary (BNF) codes 3.1.1–3.1.4, 3.2, 3.3). If a patient 
was not diagnosed with a code for asthma, this child 
was labelled as non-asthmatic. Children with a diagnose 
code of asthma and less than two prescriptions of asthma 
drugs were excluded from analyses because of potential 
misclassification
exposure
All antibiotic (AB) prescriptions during the study period 
were identified from the patient files by an automated 
search on antibiotic drug codes (ATC code J01 for IPCI 
and BNF code 5.1 for THIN). To enable comparison 
between countries, BNF codes were mapped to the corre-
sponding ATC codes.
Indications
To assess the underlying indications, the main indication 
code (Read codes in the THIN database and ICPC codes 
in the IPCI database) linked to the prescription was used. 
Only if no indication code of an infection was linked to the 
prescription, diagnostic codes entered in the patient’s file 
on the same date as the antibiotic prescription were also 
considered as indication of use. Indications were divided 
into the following categories: upper respiratory tract 
infections (URTIs), skin infections (skin), urinary tract 
infections (UTI), asthma exacerbation (asthma), lower 
respiratory tract infections (LRTIs) and a combination 
of URTI and LRTI in case a patient had codes for both. 
Other indications were categorised as ‘other’, and since 
there were not many prescriptions with multiple indica-
tions, we categorised those as ‘other’ as well. As we were 
especially interested in LRTI, we categorised subtypes 
of LRTI’s into ‘bronchitis’, ‘pneumonia’, ‘combination 
of asthma exacerbation and bronchitis’, ‘influenza’, 
‘tracheitis’, ‘unspecified’ (if no further categorisation 
was possible) and ‘other’ (other LRTI or combinations of 
the previous). Tables with all indication codes and corre-
sponding categories are available in online supplemen-
tary file 1.
Quality indicators
To investigate differences in quality of antibiotic prescrip-
tions in children with and without asthma, QIs were 
calculated as proposed by the European Surveillance 
of Antimicrobial Consumption and as described in 
literature.14 First, the types of antibiotics that covered 
90% of AB prescriptions (drug utilisation 90%) were 
assessed.15–17 Second, the ratio between broad-spectrum 
and narrow-spectrum antibiotics (B/N ratio) was calcu-
lated. Two additional QIs that are specific for outpatient 
paediatric use were also investigated namely the amoxi-
cillin index (AI, the number of amoxicillin prescriptions 
as percentage of total antibiotic prescriptions) and the 
ratio between amoxicillin and broad-spectrum antibiotics 
prescriptions (A/B ratio). Although amoxicillin is classi-
fied as an intermediate-spectrum antibiotic and therefore 
not in the B/N ratio, it is considered the antibiotic of first 
choice for a large part of paediatric indications.8 18 19 A 
high AI and A/B ratio are therefore indications of appro-
priate prescribing. Antibiotics considered as broad 
spectrum were: combinations of penicillins (J01CR), 
second-generation and third-generation cephalosporins 
(J01DC, J01DD) and macrolides (J01F) (except erythro-
mycin). Narrow-spectrum antibiotics were: β-lactam sensi-
tive antibiotics (J01CE), first-generation cephalosporins 
(J01DB) and erythromycin (J01FA01).
statistical analysis
Descriptive statistics were used to describe characteristics 
of children with or without asthma. The prevalence of 
antibiotic use was expressed as the number of users per 
1000 person years (PY) to be interpreted as the number of 
children per 1000 who use antibiotics in 1 year. Antibiotic 
use was studied overall but also by type of antibiotic (ATC 
code pharmacological subgroup level). A Poisson regres-
sion model was applied to determine differences in anti-
biotic prescription rates. The effect of age, gender and 
calendar year was studied by means of a stratified anal-
ysis. Descriptive statistics were used to describe patient 
characteristics.
Χ2 tests or Fisher’s exact test were used to examine 
differences in indication of use between children with 
asthma and children without asthma. CIs of propor-
tions were derived using Wilson method for binomial 
proportions.
A p value <0.05 was considered statistically signifi-
cant. Jerboa, a custom-built software, was used to assess 
prevalence of antibiotic use and further analyses were 
conducted using SASV.9.4.20
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results
The study population of IPCI consisted of 26 750 children 
with asthma and 330 916 children without asthma in total 
contributing to 946 143 PY. The median age for children 
with asthma at start of follow-up was 10.8 years (IQR 
6.4–14.6) and for children without asthma 10.3 years 
(IQR 6.1–13.9). The study population in THIN consisted 
of 152 957 children with asthma and 1 438 097 chil-
dren without asthma, in total contributing to 7 241 271 
PY. Median age at start of follow-up was 7.9 years (IQR 
5.0–11.4) for children with asthma and 6.0 years (IQR 
5.0–10.2) for children without asthma.
During the study period, 186 195 prescriptions of 
antibiotics were retrieved from the IPCI database and 
3 283 887 from the THIN database. The overall annual 
prevalence of AB use in the entire paediatric popula-
tion was 131/1000 PY for IPCI and twice as high, namely 
263/1000 PY for THIN (p<0.001) (figure 1). In both data-
bases, children with asthma used significantly more anti-
biotics than children without asthma (p<0.0001). In IPCI, 
the prevalence rate ratio (PRR) of AB use in children 
with asthma versus use in non-asthmatic children was 
1.65 (95% CI 1.53 to 1.78) (adjusted for age, gender and 
calendar year). The same trend was observed in THIN 
with a PRR of 1.60 (95% CI 1.54 to 1.66). The number 
of AB prescriptions was higher than the number of users 
and children who used antibiotics received on average 
two antibiotic prescriptions per year. In both databases, 
the rate of antibiotic prescriptions decreased significantly 
with calendar time, both in children with or without 
asthma (p<0.05) (figure 2).
In IPCI, 29% of the antibiotic prescriptions could not 
be linked to an indication of use on the day of prescrip-
tion; this was 50% for THIN. Of those prescriptions with 
a known indication, the most common indication in all 
children was URTI (41% IPCI, 47% THIN), followed 
by LRTIs with significantly higher proportions in chil-
dren with asthma (18% IPCI, 21% THIN) than children 
without asthma (IPCI: 13%, THIN: 12%, p value for both 
databases <0.001) (figure 3). The most common LRTI for 
which AB were prescribed was acute bronchitis (figure 4).
In children with asthma, 14% (IPCI) to 4% (THIN) of 
antibiotics were prescribed for asthma exacerbation only. 
Compared with the THIN database, a smaller proportion 
of the prescriptions for asthmatics in IPCI were due to 
URTI, LRTI and skin infections, and a larger proportion 
in IPCI was due to UTI and asthma (p value for all indi-
cations <0.001). Differences in prescriptions for non-asth-
matic patients were mostly similar, except that in these 
cohorts more prescriptions were due to LRTI in IPCI 
than in THIN (13% vs 12%, p value <0.001).
The type of prescribed AB was different between data-
bases (figures 5-6, table 1). In IPCI, the difference in type 
of antibiotic between children with and without asthma 
was most pronounced for macrolides (22.1% of all AB 
prescriptions in children with asthma vs 15.9% in non-asth-
matic children, p value <0.0001). In THIN, this differ-
ence was less pronounced: macrolides were prescribed 
in 15.4% of prescriptions for children with asthma and 
12.9% for children without asthma (p<0.0001).
With regard to QIs, less appropriate antibiotic 
prescribing was observed for IPCI (Netherlands) 
compared with THIN (UK), with a higher B/N ratio 
(IPCI: 3.4, THIN: 0.3, p<0.001) and a lower A/B ratio 
(IPCI: 1.1, THIN: 3.9, p<0.001) and AI (IPCI: 32.0, THIN: 
36.1, p<0.001) in IPCI than in THIN. These findings 
remained when repeating the analysis for prescriptions 
for LRTI only. Overall, based on QIs, AB prescribing in 
children with asthma appeared less appropriate than in 
children without asthma (table 2).
Figure 1 Age and asthma status-specific annual 
prevalence rate of antibiotic use. IPCI, Integrated Primary 
Care Information database; THIN, The Health Improvement 
Network; PY, person years.
Figure 2 Annual prevalence rate of antibiotic use by 
calendar year. IPCI, Integrated Primary Care Information 
database; THIN, The Health Improvement Network; PY, 
person years. 
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The analyses of prescription rates, indications and QIs 
were repeated while stratifying for age and gender. After 
the age of 12, especially in girls, the number of prescrip-
tions increased due to UTIs. Differences between chil-
dren with and without asthma and between countries 
remained similar on stratification. Details on stratified 
analysis are available in online supplementary file 2.
DIsCussIOn
In this international cohort study, we showed that chil-
dren with asthma are more often prescribed antibiotics 
than children without asthma. This higher AB prescrip-
tion rate in children with versus children without asthma 
was strikingly similar in the UK and the Netherlands, 
while overall use of AB prescriptions was substantially 
higher in the UK compared with the Netherlands. High 
use of AB in children with asthma was already reported 
in literature but, to our knowledge, we are the first who 
investigated indication of use.5 6
The indications of use were often bronchitis and 
asthma exacerbations, conditions for which antibiotics 
are in general not recommended. Indeed, according 
Figure 3 Indications of antibiotic use: proportion of known indications. IPCI, Integrated Primary Care Information database; 
LRTI, lower respiratory tract infection; SKIN, skin infection; THIN, The Health Improvement Network; URTI, upper respiratory 
tract infection; UTI, urinary tract infection. 
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to the guidelines of the Global Initiative of Asthma, use 
of AB for the treatment of asthma exacerbations is not 
recommended unless there is strong evidence of lung 
infection.7 Asthma is not a risk factor for complicated 
respiratory tract infections according to the British guide-
lines, and Dutch guidelines even emphasise that under-
lying asthma does not justify antibiotics in case of a LRTI.8 9 
Additionally, it has been shown that asthma is not a risk 
factor for complications of influenza.21 One explanation 
for increased antibiotic prescribing for children with 
asthma could be that respiratory infectious syndromes 
in children with asthma present with various lower respi-
ratory tract symptoms. This complicates the discrimina-
tion between a bacterial infection, a viral infection or an 
asthma exacerbation in primary care. Also, even though 
guidelines state that there is not enough evidence for 
treatment with antibiotics in case of an asthma exacerba-
tion, it is being discussed that the supposedly anti-inflam-
matory effect of antibiotics (macrolides in particular) 
might be beneficial for patients with asthma.22–25 This 
might explain the relatively higher rate of macrolides 
prescriptions for asthmatic children in the Netherlands. 
However, the recommendation of macrolide use would 
only be beneficial for children with severe asthma whom 
are usually treated in secondary and tertiary care.
For the overall use of antibiotics in all children, it is 
remarkable that a large proportion was prescribed for 
URTIs. URTIs are notoriously caused by viruses for which 
Figure 4 Indications of lower respiratory tract infections. IPCI, Integrated Primary Care Information database; THIN, The Health 
Improvement Network. 
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antibiotics are not effective.9 This is supported by the 
observation that in IPCI, along with lower prescribing 
rates, less prescriptions were due to LRTI and URTI than 
in THIN. These findings suggest need for better guide-
lines on treatment of URTI and monitoring systems at the 
different points of care (general practitioner (GP), phar-
macist, secondary care) for incorrect use of AB.
The majority of URTIs and LRTIs are caused by viruses 
not requiring AB treatment. Early identification of 
bacteria as causal organism might be a tool for guided AB 
treatment. Reviews of randomised trials show that C reac-
tive protein (CRP) testing and procalcitonin-guided 
management can reduce antibiotic prescriptions, without 
negative impact on disease duration.26 Similarly, delayed 
instead of immediate antibiotic prescribing which is 
already implemented in UK guidelines and shared deci-
sion-making could benefit antibiotic rates.26 27 However, 
most studies on these tests have been done in adults. 
For this reason, Dutch guidelines advise the use of CRP 
testing in adults only with certain respiratory symptoms 
while awaiting more evidence of safety of use in children.8 
Education of the patients should not be forgotten, as the 
patient’s view on treatment influences the decision of 
physicians.28–30 While important differences in prescrip-
tion rates were observed in children with or without 
asthma, the type of drugs and quality of the prescriptions 
Figure 5 Age, gender and asthma-specific antibiotic prescriptions in the Integrated Primary Care Information database.
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were comparable. Although differences between asth-
matics and non-asthmatics were statistically significant, 
compared with differences between countries they were 
almost negligible. Mainly country-specific differences in 
QIs were observed which was already reported in other 
studies.31 Although children in the UK receive twice as 
often antibiotics compared with Dutch children, the 
choice of antibiotics seems to be more appropriate in 
the UK. These country-specific differences in QIs might 
be explained by differences in availability of drugs, resis-
tance patterns and national guidelines.
As for all observational research, this study has strengths 
and limitations: strengths of this study include the large 
number of patients that were followed over time and 
the fact that this is an international study. In addition, 
we present real life data, by using the electronic patient 
records of GP practices spread over the UK and the Neth-
erlands. In both countries, the GP acts as a gatekeeper 
of the patient’s medical care, minimising selection and 
information bias. Also, in contrast to other studies, we had 
information on all different indications of use, although 
not for all AB prescriptions. With regard to limitations, 
we might have under-reported pneumonia as indica-
tion of AB use in THIN. In our study, pneumonia was 
defined based on pneumonia-specific Read codes. This 
classification was stricter than in other studies where the 
Figure 6 Age, gender and asthma-specific antibiotic prescriptions in The Health Improvement Network.
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Read code ‘Acute lower respiratory infection (H062.00)’ 
was also classified as ‘pneumonia’ while we classified 
that code as ‘LRTI—unspecified’.32 For both databases, 
indications were based on diagnose codes without use of 
free text. The system automatically links a drug with the 
problem code it is prescribed within. In a busy consul-
tation, all the prescriptions might be issued under one 
problem code. In the UK, performing an asthma review is 
part of the quality and outcomes framework which might 
lead to extra entries for asthma if a patient presents with 
another disease. For drugs with a single indication of use, 
this problem can be identified. In the IPCI and THIN 
databases, 98% and 94% of the minocycline prescrip-
tions were linked to skin infections, respectively, and 98% 
and 96% of nitrofurantoin prescriptions were linked to 
UTIs, respectively. This suggests limited bias. Still, the 
bias might be more likely to occur in indications from the 
same system organ class—such as LRTI and asthma, but 
this can only be identified through free text validation. 
Finally, misclassification of asthma could be a concern 
as asthma was based on the presence of asthma disease 
codes in combination of use of respiratory drugs: still 
the prevalence of asthma which we reported (IPCI 7.9% 
and THIN 9.6%) is in line with literature suggesting that 
asthma misclassification is minimal.33
To conclude, this study shows possibilities for further 
reduction and more sensible choice of antibiotic use, 
even in countries such as the Netherlands where antibi-
otic use is the lowest in the world. We showed that chil-
dren with asthma are prescribed antibiotics often for 
self-limiting respiratory tract infections. Additionally, 
asthma treatment in primary care can be optimised by 
following (inter)national guidelines more strictly in 
terms of prescription rates and type of drugs. This can be 
done by raising awareness among GPs, patients and their 
parents. Additionally, careful implementation of point-of 
care tests such as CRP testing and procalcitonin-guided 
management in guidelines will help in reducing antibiotic 
Table 1 DU90% of all prescriptions in IPCI and THIN
Drug
Active component
Percentage of DU90% (95% CI) Asthma vs no asthma
Pharmacological 
subgroup asthma no asthma P values
IPCI
Tetracyclines Doxycycline 7.0% (6.6–7.4) 6.6%
(6.5–6.7)
0.0092
Minocycline N/A 3.6%
(3.5–3.7)
N/A
Penicillins Amoxicillin 37.5% (37.0–38.4) 34.5% (34.3–34.8) <0.0001
Pheneticillin 5.2% (4.9–5.5) 7.7% (7.6–7.8) <0.0001
Flucloxacillin 5.0% (4.6–5.3) 6.3%
(6.2–6.4)
<0.0001
Amoxicillin with enzyme inhibitor 12.6% (12.1–13.1) 14.2% (14.0–14.4) <0.0001
Sulfonamides and 
trimethoprim
Sulfamethoxazole and 
trimethoprim
3.8% (3.6–4.1) N/A N/A
Macroliden, lincosamides 
and streptogramins
Clarithromycin 8.1% (7.7–8.5) 5.6%
(5.5–5.7)
<0.0001
Azithromycin 13.8% (13.4–14.4) 10.1% (10.0–10.3) <0.0001
Other antibacterials Nitrofurantoin 6.9% (6.5–7.2) 11.5% (11.3–11.6) <0.0001
THIN
Tetracyclines lymecycline 4.1% (4.0- 4.1) 4.8% (4.8- 4.9) <0.0001
oxytetracycline 3.2% (3.1- 3.2) 3.5% (3.5- 3.5) <0.0001
Penicillins amoxicillin 38.8% (38.7- 39) 33.7% (33.8-33.9) <0.0001
phenoxymethylpenicillin 13.9% (13.7- 14.0) 18.4% (18.3-18.4) <0.0001
flucloxacillin 12.2% (12.1- 12.3) 14.0% (14.0-14.0) <0.0001
amoxicillin with enzyme enhibitor 4.3% (4.3- 4.4) 4.4% (4.4- 4.5) 0.0178
Other b-lactam 
antibacterials
Cefalexin 3.2% (3.1–3.2) 3.1% (3.1–3.1) <0.0001
Sulfonamides and 
trimethoprim
Trimethoprim 5.2% (5.1–5.3) 7.0% (7.0–7.0) <0.0001
Macroliden, lincosamides 
and  streptogramins 
erythromycin 12.1% (12.0- 12.2) 11.0%  (11.0-11.1) <0.0001
clarithromycin 3.2% (3.1- 3.2) N/A N/A
DU90%, drug utilisation 90%; IPCI, Integrated Primary Care Information database; N/A, not part of DU90%; THIN, The Health Improvement 
Network.
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therapy rates. Further awareness can reduce unnecessary 
antibiotic use and limit antibiotic resistance.
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